Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis

PURPOSE: REACH investigated second-line ramucirumab therapy for advanced hepatocellular carcinoma. RESULTS: Median overall survival was 8.2 months for ramucirumab and 6.9 months for placebo (HR, 0.835; 95% CI, 0.634–1.100; p = 0.2046) for East Asians, and 10.1 months for ramucirumab and 8.0 months f...

Full description

Saved in:
Bibliographic Details
Published in:Oncotarget
Main Authors: Park, Joon Oh, Ryoo, Baek-Yeol, Yen, Chia-Jui, Kudo, Masatoshi, Yang, Ling, Abada, Paolo B., Cheng, Rebecca, Orlando, Mauro, Zhu, Andrew X., Okusaka, Takuji
Format: Artigo
Language:Inglês
Published: Impact Journals LLC 2016
Subjects:
Research Paper
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342754/
https://ncbi.nlm.nih.gov/pubmed/27776351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.12780
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items